Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Universal Ibogaine Inc ( (TSE:IBO) ) has issued an update.
Universal Ibogaine Inc. has reached a debt settlement agreement involving $106,200 in consulting fees owed to its CEO, Nicholas Karos, by issuing common shares. The company has also resolved a Cease Trade Order from the Alberta Securities Commission by filing overdue financial statements, allowing the resumption of trading of its shares pending TSXV review.
More about Universal Ibogaine Inc
Universal Ibogaine Inc. is a life sciences company focused on transforming addiction treatment through medicalized ibogaine, with plans for a Canadian clinical trial targeting opioid use disorder. The company aims to globally license its treatment protocol and is developing a holistic addiction treatment protocol at its Kelburn Recovery Centre in Manitoba.
YTD Price Performance: 150.0%
Average Trading Volume: 212,110
Technical Sentiment Signal: Sell
Current Market Cap: C$6.87M
See more insights into IBO stock on TipRanks’ Stock Analysis page.